97185 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor
COMPOSITIONS AND METHODS
#2ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
#3BINDING MOLECULES TO TUMOR ASSOCIATED MACROPHAGES AND METHODS OF USE
#4FUSION CONSTRUCTS AND METHODS OF USING THEREOF
#5Anti-FOLR1 Immunoconjugate Dosing Regimens
#6METHOD FOR TREATING CLONAL HEMATOPOIETIC BLOOD DISORDERS
#7ANTIBODIES TARGETING LIV-1 AND USES THEREOF
#8METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE
#9HIF-1a INHIBITOR
#10Antibodies targeting LIV-1 and uses thereof
#11METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE
#12Methods and Compositions for Diabetes Treatment and Beta-Cell Regeneration
#13FIBRONECTIN BASED SCAFFOLD PROTEINS
#14SYSTEMS AND METHODS FOR TREATING CANCER
#15FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
#16HIF-1a MODULATORS AND USES THEREOF
#17Anti-FOLR1 Immunoconjugate Dosing Regimens
#18FIBRONECTIN BINDING DOMAINS WITH REDUCED IMMUNOGENICITY
#19Fusion constructs and methods of using thereof
#20Modulators of ROR1-ROR2 binding
#21MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS
#22BINDNG MOLECULES TO TUMOR ASSOCIATED MACROPHAGES AND METHODS OF USE
#23Variants of human BMP7 protein
#24DOSING REGIMES FOR TREATMENT OF SYNUCLEINOPATHIES
#25Compositions and methods for treating HIF-1a over-expressing cancers
#26Fibronectin binding domains with reduced immunogenicity
#27TREATMENT OF AGE-RELATED AND MITOCHONDRIAL DISEASES BY INHIBITION OF HIF-1 ALPHA FUNCTION
#28Fibronectin based scaffold proteins
#29Fibronectin binding domains with reduced immunogenicity
#30Anti-FOLR1 Immunoconjugate Dosing Regimens
#31Anti-nucleolin antibodies
#32DOSING REGIMES FOR TREATMENT OF SYNUCLEINOPATHIES
#33SUBSTANCE THAT INHIBITS P2Y12 RECEPTOR, FOR USE IN THE PREVENTIVE TREATMENT OF SYSTEMIC SCLEROSIS IN PATIENTS WITH RAYNAUD'S PHENOMENON AND A DYSIMMUNITY
#34Monocyte modulation and control of tumor metastasis
#35Anti-ROR2 antibodies
#36TREATMENT OF AGE-RELATED AND MITOCHONDRIAL DISEASES BY INHIBITION OF HIF-1 ALPHA FUNCTION
#37Modulators of ROR1-ROR2 binding
#38CHIMERIC RABBIT/HUMAN ROR1 ANTIBODIES
#39Fibronectin binding domains with reduced immunogenicity
#40Fibronectin binding domains with reduced immunogenicity
#41Protein binding domains stabilizing functional conformational states of GPCRs and uses thereof
#42Compositions and methods for treating HIF-1α over-expressing cancers
#43Androgen receptor variants and methods for making and using
#44Fibronectin binding domains with reduced immunogenicity
#45Anti-FOLR1 Immunoconjugate Dosing Regimens
#46Chimeric rabbit/human ROR1 antibodies
#47Fibronectin binding domains with reduced immunogenicity
#48Fibronectin binding domains with reduced immunogenicity
#49Anti-human ROR1 antibodies
#50METHOD OF INCREASING METABOLISM
#51AUTO-ANTIBODY MARKERS OF AUTOIMMUNE DISEASE
#52Estrogen Related Receptor, ERRalpha, A Regulator of Bone Formation
#53Treatment of Heart Failure
#54Receptor In Dendritic Cells
#55Rhesus monkey Nur77
#56ANTIBODY DESIGNATED BARB3, BARB3 RELATED ANTIBODIES, AND METHODS OF MAKING AND USING SAME
#57Conversion of apoptotic proteins
#58Conversion of apoptotic proteins
#59Methods for ex vivo propagation of adult hepatic stem cells
#60Rhesus monkey Nur77
#61Estrogen related receptor, ERRα, a regulator of bone formation
#62Conversion of apoptotic proteins
#63Monoclonal antibody specific for PPAR gamma, hydridoma cell line producing the same, and method for detecting regulator related to diseases, including inflammation, cancer and metabolic diseases, using the same
#64Methods and compositions related to inhibiting nuclear envelope breakdown
#65Neuropilin-1-peptide based antibody, highlighting new epitope associated to glycosaminoglycan-modified neuropilin-1 and methods of use thereof